



**FOR RELEASE**

**Embargoed Until May 19, 2:45 p.m. CT**

**FOR MORE INFORMATION, CONTACT:**

Dacia Morris

dmorris@thoracic.org

ATS Office 212-315-8620 (until May 16)

Session: A97 Station to Station: Unraveling the Molecular Pathogenesis of PAH

Abstract Presentation Time: Sunday, May 19, 2:45 p.m. CT

Location: Room C147, 148 and 154 (Level 1), Kay Bailey Hutchison Convention Center Dallas

## **TUMOR-SUPPRESSING PROTEIN MAY BE NOVEL TARGET IN PAH THERAPY**

ATS 2019, Dallas, TX – In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating [pulmonary arterial hypertension](#) (PAH), according to research presented at ATS 2019. Researchers found that a deficiency of this protein produced dysfunctional molecules unable to support cell structure and function, resulted in thickening of pulmonary blood vessels and led to PAH.

**[VIEW ABSTRACT](#)**

**CONTACT FOR MEDIA**

Yuanjun Shen, PhD

sheny@pitt.edu